Contineum Therapeutics (CTNM) Announces Proposed IPO

Contineum Therapeutics (NASDAQ: CTNM) has filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need."

Goldman Sachs & Co, Morgan Stanley, Stifel and RBC Capital Markets will serve as lead underwriters.

You May Also Be Interested In

• Bunge prices $600 million senior notes offering due 2031
• Karman Line Acquisition prices $200M IPO on Nasdaq
• NorthStrive Acquisition prices $100M IPO on Nasdaq